Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

This publication has 20 references indexed in Scilit:

• Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
  New England Journal of Medicine, 2013
• Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
  Antimicrobial Agents and Chemotherapy, 2013
• Long-acting injectable antiretrovirals for HIV treatment and prevention
  Current Opinion in HIV and AIDS, 2013
• Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
  The Lancet, 2013
• A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
• Dolutegravir in antiretroviral-naive adults with HIV-1
  AIDS, 2013
• Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies
  HIV Research & Clinical Practice, 2013
• Quad's in it for antiretroviral therapy?
  The Lancet, 2012
• Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
  The Journal of Infectious Diseases, 2010
• Analyzing Sleep Abnormalities in HIV‐Infected Patients Treated with Efavirenz
  Clinical Infectious Diseases, 2004